Craniopharyngioma After Neurosurgery Falls Short — No Raised ICP, No Vision Loss
This protocol addresses craniopharyngioma patients in a clinically stable, non-urgent state — no raised intracranial pressure and no vision loss — in whom initial surgical management did not achieve its intended goals. With no imminent threat to vision or neurological function, a structured personalised plan determined through multidisciplinary discussion is required before the next treatment step is taken.
Clinical Scenario
The patient has craniopharyngioma with no raised intracranial pressure and no vision loss, placing them in the "no imminent threat" category. Patients in this situation should undergo personalised treatment after a multidisciplinary discussion.
Why the First-Line Surgical Approach Was Insufficient
Initial management — neurosurgery (resection guided by tumour grade and hypothalamic involvement, or intracystic interferon-alpha therapy for predominantly cystic lesions) — aimed to achieve shrinkage of cyst volume with relief of mass-effect on the optic pathways while preserving pituitary function, and to confirm no residual disease on early postoperative MRI. When those goals are not reached, or when disease progresses during an initial watchful-waiting period, escalation to the next treatment line is indicated.
Next-Line Approach
The next step involves highly conformal image-guided adaptive radiotherapy — delivered with either photons or protons — with precise daily position corrections. The timing and choice of technique are individualised according to clinical factors. The full regimen, decision criteria, and technical specifications are available in the complete protocol.
References
- Patients with no imminent threats should undergo personalized treatment after a multidisciplinary discussion.
- A total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy, using image-guided adaptive radiotherapy with daily online position corrections should be considered as gold standard.
- Depending on age, tumour location and extent, and pituitary function the timing of radiotherapy can be chosen shortly after limited surgery or to be delayed to till progression is evident.
- Depending on target volume size and extension, a benefit of proton therapy can be expected in a subgroup of patients.